Abstract
Among neonatal cardiomyopathies, primary endocardial fibroelastosis (pEFE) remains a mysterious disease of the endomyocardium that is poorly genetically characterized, affecting 1/5000 live births and accounting for 25% of the entire pediatric dilated cardiomyopathy (DCM) with a devastating course and grave prognosis. To investigate the potential genetic contribution to pEFE, we performed integrative genomic analysis, using whole exome sequencing (WES) and RNA-seq in a female infant with confirmed pathological diagnosis of pEFE. Within regions of homozygosity in the proband genome, WES analysis revealed novel parent-transmitted homozygous mutations affecting three genes with known roles in cilia assembly or function. Among them, a novel homozygous variant [c.1943delA] of uncertain significance in ALMS1 was prioritized for functional genomic and mechanistic analysis. Loss of function mutations of ALMS1 have been implicated in Alstrom syndrome (AS) [OMIM 203800], a rare recessive ciliopathy that has been associated with cardiomyopathy. The variant of interest results in a frameshift introducing a premature stop codon. RNA-seq of the proband’s dermal fibroblasts confirmed the impact of the novel ALMS1 variant on RNA-seq reads and revealed dysregulated cellular signaling and function, including the induction of epithelial mesenchymal transition (EMT) and activation of TGFβ signaling. ALMS1 loss enhanced cellular migration in patient fibroblasts as well as neonatal cardiac fibroblasts, while ALMS1-depleted cardiomyocytes exhibited enhanced proliferation activity. Herein, we present the unique pathological features of pEFE compared to DCM and utilize integrated genomic analysis to elucidate the molecular impact of a novel mutation in ALMS1 gene in an AS case. Our report provides insights into pEFE etiology and suggests, for the first time to our knowledge, ciliopathy as a potential underlying mechanism for this poorly understood and incurable form of neonatal cardiomyopathy.Key messagePrimary endocardial fibroelastosis (pEFE) is a rare form of neonatal cardiomyopathy that occurs in 1/5000 live births with significant consequences but unknown etiology.Integrated genomics analysis (whole exome sequencing and RNA sequencing) elucidates novel genetic contribution to pEFE etiology.In this case, the cardiac manifestation in Alstrom syndrome is pEFE. To our knowledge, this report provides the first evidence linking ciliopathy to pEFE etiology.Infants with pEFE should be examined for syndromic features of Alstrom syndrome.Our findings lead to a better understanding of the molecular mechanisms of pEFE, paving the way to potential diagnostic and therapeutic applications.
Highlights
Cardiomyopathy is a heterogenous group of disorders mainly characterized by abnormal ventricular hypertrophy or dilation leading to ventricular dysfunction [1, 2]
Human studies All human studies were conducted in accordance with regulation of the University of California Los Angeles (UCLA) Institutional Review Board (IRB)
Electronic medical record, family pedigree, and specimen collection were acquired through the UCLA Congenital Heart Defect (CHD) BioCore [24] following the UCLA-IRB-approved protocols
Summary
Cardiomyopathy is a heterogenous group of disorders mainly characterized by abnormal ventricular hypertrophy or dilation leading to ventricular dysfunction [1, 2]. Mendelian inheritance appears to exist in approximately 50% of pediatric DCM. As in other cardiomyopathy forms, mitochondrial disorders, metabolic disease, chromosomal defects, and dysmorphic syndromes may underlie the majority of cases that present early during infancy. Monogenic autosomal and X-linked inheritance have been reported in DCM cases that present in children less than 18 years of age, of which a substantial subgroup of DCM cases has been associated with skeletal myopathy and/or conduction system disease. 43% of pediatric DCM cases remain with unidentified cause. Elucidating the underlying genetic etiology is crucial to provide early diagnosis, risk stratification, prognostication, and follow-up of at risk relatives
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have